Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Editas Medicine Inc EDIT

Healthcare Biotechnology
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9... see more

Recent & Breaking News (NDAQ:EDIT)

Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

GlobeNewswire January 25, 2018

Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference

GlobeNewswire January 8, 2018

22 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  January 8, 2018

Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2018

5 Stocks Moving In Wednesday's After-Hours Session

Benzinga.com  December 20, 2017

Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia

GlobeNewswire December 11, 2017

Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock

GlobeNewswire December 6, 2017

9 Stocks Moving In Tuesday's After-Hours Session

Benzinga.com  December 5, 2017

Editas Medicine, Inc., Announces Offering of Common Stock

GlobeNewswire December 5, 2017

Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team

PR Newswire November 14, 2017

Barclays: Editas Medicine On Track To File New Drug App Next Year

Benzinga.com  November 8, 2017

Editas Medicine Announces Third Quarter 2017 Results and Update

GlobeNewswire November 7, 2017

Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results

GlobeNewswire November 3, 2017

Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice

GlobeNewswire October 19, 2017

Editas Medicine to Participate in Investor Conferences in October

GlobeNewswire October 3, 2017

Editas Medicine Receives EMA’s Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10

GlobeNewswire September 26, 2017

Biotech Stocks on Investors' Radar -- Clovis Oncology, Dermira, Editas Medicine, and Endocyte

PR Newswire September 15, 2017

Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)

GlobeNewswire September 12, 2017

Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference

GlobeNewswire September 5, 2017

Editas Medicine Announces Second Quarter 2017 Results and Update

GlobeNewswire August 9, 2017